The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire has helped spotlight the growing virtual biotech model.
Biogen Idec ($BIIB) has scooped up a biotech very close to home. The Weston, MA-based biotech power has bought nearby Stromedix, whose lead fibrosis drug STX-100 was licensed from Biogen. The deal
Stromedix CEO Michael Gilman appears to be making headway in his quest to round up an additional $15 million in venture funds for his virtual biotech. Quoting documents filed with the feds, Mass High
When Cambridge, MA-based Stromedix raised $25 million in 2008, CEO Michael Gilman said he hoped to have the company's lead drug, STX-100, well into Phase II trials by mid-2010. The drug, which was
Cambridge, MA-based Stromedix has landed $25 million in a Series B round of venture capital. The company's lead drug is STX-100, a humanized monoclonal antibody which Stromedix is developing for